Dr. Kiss's research career started as an undergraduate at Columbia University where, in conjunction with the National Aeronautics and Space Administration and the Kennedy Space Center, he evaluated the implications of microgravity on early developmental patterning. Dr. Kiss was involved in scientific experiments launched on the space shuttle Discovery and the space shuttle Columbia. Dr. Kiss's research interests include basic science, translational and clinical research in ophthalmology. With the support of the Heed Ophthalmic Foundation, Dr. Kiss studied the efficacy and safety of a gene therapy approach for the treatment of neovascular complications of age-related macular degeneration. Dr. Kiss received the Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute Joint Clinical Research Center Pilot Project Grant to examine the role of Bruch's membrane in neovascular age-related macular degeneration. He studied elastic fiber homeostatis in choriodal neovascular membrane formation in the setting of lysyl oxidase-like 1 protein deficiency. Dr. Kiss's interest in improving vitreo-retinal surgical techniques led to the description of a transconjunctival sutureless pars plana vitrectomy procedure for the removal of retained lens fragments and intraocular foreign bodies. Dr. Kiss is also investigating the use of small gauge microcannula-based pars plana vitrectomy for the management of vitreoretinal complications in eyes with permanent keratoprosthesis. Dr. Kiss has been involved as a sub-investigator in clinical trials examining the role of ranibizumab (Lucentis) in the treatment of choroidal neovascularization secondary to age-related macular degeneration, choroidal neovascularization secondary to causes other than age-related macular degeneration, macular edema secondary to diabetes mellitus, and macular edema due to central or branch retinal vein occlusion. Dr. Kiss was also a participant in the evaluation of the efficacy and safety of posterior juxtascleral administrations of anecortave acetate in patients at risk for developing choroidal neovascularization due to exudative age-related macular degeneration. Additionally, Dr. Kiss participated in trials assessing the safety and efficacy of a dexamethasone posterior segment drug delivery system (DEX PS DDS Applicator System) in the treatment of patients with diabetic macular edema and in patients with macular edema following central or branch retinal vein occlusion.